Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 10/20 | 0.72 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.53 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | MITF | O75030 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29437404 | 1.00 | POLB (1.00) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17055347 | 0.94 | POLB (0.89) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL2724789 | 0.87 | POLB (0.76) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL20150158 | 0.86 | POLB (0.75) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23132947 | 0.86 | POLB (0.74) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL29435521 | 0.85 | MAPT (0.97) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL3539759 | 0.85 | MAPT (0.90) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL15141576 | 0.85 | MAPT (0.97) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23104310 | 0.85 | POLB (0.72) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23109102 | 0.85 | POLB (0.72) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 437 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2025-08-26 | — | — | US | disclosed |
| EP-4596051-A2 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | Pharmacosmos Holding A/s (DK) | 2025-08-06 | — | — | EP | disclosed |
| US-12358904-B2 | Inhibitors of TYK2 | Atomwise Inc. (US) | 2025-07-15 | — | — | US | disclosed |
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | PHARMACOSMOS HOLDING A/S (DK) | 2025-04-29 | — | — | US | disclosed |
| EP-2968291-B1 | HSPC-SPARING TREATMENTS FOR RB-POSITIVE ABNORMAL CELLULAR PROLIFERATION | PHARMACOSMOS HOLDING AS (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| US-20240417396-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-19 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2007131991-A1 | IMIDAZOLOPYRAZINE COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2007-11-22 | — | — | WO | disclosed |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY | 2007-08-02 | — | — | US | disclosed |
| CN-101001857-A | 2- (pyridin-2-ylamino) -pyrido [2, 3-d ] pyrimidin-7-ones | WARNER LAMBERT CO (US) | 2007-07-18 | — | — | CN | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12285431-B2 | Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors | RB1, CDK4, CDK6 | POLB 139/4885MAPT 3872/4885RAB9A 2394/4885 |
| US-20240417396-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | POLB 3285/4885MAPT 1028/4885RAB9A 3603/4885 |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | POLB 3838/4885MAPT 3432/4885RAB9A 1986/4885 |
| US-12358904-B2 | Inhibitors of TYK2 | TYK2, LCK, JAK2 | POLB 3285/4885MAPT 1028/4885RAB9A 3603/4885 |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | POLB 1161/4885MAPT 3765/4885RAB9A 3487/4885 |
| US-12398132-B2 | Derivatives of 4-(imidazo[1,2-a]pyridin-3-yl)-n-(pyridinyl)pyrimidin-2-amine as therapeutic agents | FLT3, CDK2, CDK4 | POLB 664/4885MAPT 3940/4885RAB9A 3906/4885 |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | CDK4, CDK2, CDKL4 | POLB 1017/4885MAPT 3714/4885RAB9A 3656/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | POLB 1169/4885MAPT 3732/4885RAB9A 3487/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | POLB 3285/4885MAPT 1028/4885RAB9A 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.